3.25  0.25 (8.33%)		04-26 15:54
Open: 2.9 High: 3.25 Volume: 4,706		Pre. Close: 3 Low: 2.9 Market Cap: 21(M)

Short term
Mid term
Targets	6-month :	4.38	1-year :	5.11
Resists	First :	3.75	Second :	4.38
Pivot price	3.1
Supports	First :	3.05	Second :	2.61
MAs	MA(5) :	3.04	MA(20) :	3.13
	MA(100) :	2.9	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	68.8	D(3) :	48.9
RSI	RSI(14): 52.6
52-week	High :	6.65	Low :	1.79

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NRXS ] has closed below upper band by 17.4%. Bollinger Bands are 48.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.25 - 3.27	3.27 - 3.28
Low:	2.87 - 2.88	2.88 - 2.9
Close:	3.22 - 3.25	3.25 - 3.28

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Tue, 23 Apr 2024
NeurAxis Announces New Medical Policy Coverage in North Dakota - Yahoo Finance

Fri, 12 Apr 2024
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call Transcript - Yahoo Finance

Tue, 09 Apr 2024
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results - Yahoo Finance

Mon, 01 Apr 2024
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024 - Yahoo Finance

Wed, 27 Mar 2024
NRXS Stock Quote Price and Forecast - NeurAxis, Inc. - CNN

Wed, 27 Mar 2024
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	5 (M)
Shares Float	3 (M)
Held by Insiders	39.5 (%)
Held by Institutions	1.1 (%)
Shares Short	49 (K)
Shares Short P.Month	14 (K)

EPS	-1.86
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.21
Profit Margin	0 %
Operating Margin	-633 %
Return on Assets (ttm)	-293.5 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	-22.8 %
Gross Profit (p.s.)	0
Sales Per Share	0.48
EBITDA (p.s.)	-1.14
Qtrly Earnings Growth	0 %
Operating Cash Flow	-4 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-1.76
PEG Ratio	0
Price to Book value	-15.48
Price to Sales	6.76
Price to Cash Flow	-4.02

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.